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OBJECTIVE—Steatosisassociateswithinsulinresistanceandmayevenpredicttype2diabetes
and cardiovascular complications. Because muscular insulin resistance relates to myocellular
fat deposition and disturbed energy metabolism, we hypothesized that reduced hepatic
ATP turnover (fATP) underlies insulin resistance and elevated hepatocellular lipid (HCL)
contents.
RESEARCHDESIGNANDMETHODS—WemeasuredhepaticfATPusing
31Pmagnetic
resonance spectroscopy in patients with type 2 diabetes and age- and body mass–matched
controls. Peripheral (M and M/I) and hepatic (suppression of endogenous glucose production)
insulin sensitivity were assessed with euglycemic-hyperinsulinemic clamps.
RESULTS—Diabetic individuals had 29% and 28% lower peripheral and hepatic insulin sen-
sitivity as well as 42% reduced fATP than controls. After adjusting for HCL, fATP correlated
positivelywithperipheralandhepaticinsulinsensitivitybutnegativelywithwaistcircumference,
BMI, and fasting plasma glucose. Multiple regression analysis identiﬁed waist circumference as
an independent predictor of fATP and inorganic phosphate (PI) concentrations, explaining 65%
(P = 0.001) and 56% (P = 0.003) of the variations. Hepatocellular PI primarily determined the
alterations in fATP.
CONCLUSIONS—In patients with type 2 diabetes, insulin resistance relates to perturbed
hepatic energy metabolism, which is at least partly accounted for by fat depots.
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A
lterations in liver function are fre-
quently encountered in patients
with type 2 diabetes (1,2). Nonalco-
holic fatty liver (steatosis) and hepatic in-
sulin resistance are typical for type 2
diabetes and may even precede or con-
tribute to its development (2,3). It also
relates to the development of cardiovas-
cular diseases(4),besides theprogression
into steatohepatitis and cirrhosis (5).
Steatosis likely results from excessive
lipid overﬂow originating from aug-
mented lipid stores in peripheral or vis-
ceral adipocytes, lipogenesis, or high
dietary intake (2).
Magnetic resonance spectroscopy
(MRS) allows noninvasive direct measure-
ments of metabolite concentrations and
tracing of metabolic ﬂuxes in situ. Quan-
tiﬁcation of intramyocellular lipids and
hepatocellular lipids (HCL) by
1HM R S
revealed that both are linked to whole-
body (peripheral) insulin resistance, ab-
normal endogenous glucose production
(EGP), and liver glycogen storage in line
with hepatic insulin resistance (2). Ac-
cording to one current paradigm, ex-
cessive ectopic lipid deposition precedes
the development of type 2 diabetes (2).
Yet, the underlying metabolic processes
leading to lipid accumulation and insulin
resistance in skeletal muscle and liver are
not fully understood.
In skeletal muscle, insulin resistance
relates not only to elevated lipids but also
toimpairedratesofphosphorylation(ﬂux
throughATPsynthesis,fATP),asmeasured
by
31P MRS in elderly (6) type 2 diabetic
patients (7), their insulin-resistant ﬁrst-
degree relatives (8), and nondiabetic indi-
viduals with elevated plasma free fatty
acids (FFAs) (9).
Although it has been suggested that
nonalcoholic steatohepatitis is associated
not only with insulin resistance but also
with mitochondrial abnormalities (10),
no data on the quantiﬁcation of fATP in
patients with type 2 diabetes have been
reported so far in the human liver. Our
previous studies showed that type 2 dia-
betic individuals have lower hepatic con-
centrations of PI and ATP (11). After
developing a saturation transfer experi-
ment for assessment of hepatocellular
fATP (12), we tested the hypothesis that
type 2 diabetic patients have lower hepa-
tocellularfATPthannondiabeticcontrols,
which should relate independently of
HCL to hepatic insulin resistance.
RESEARCH DESIGN AND
METHODS—The study protocol con-
formed with the Declaration of Helsinki
(2008) and was approved by the appro-
priate institutional ethical board. In-
formed consent was obtained from each
study participant after explanation of the
purpose, nature, and potential complica-
tions of the study.
Volunteers
After recruitment by means of public
advertisement,allparticipantsunderwent
complete medical history, clinical exam-
ination, and laboratory tests to exclude
cardiovascular, renal, and thyroid dis-
eases, and viral hepatitis. All volunteers
were white and had already participated
in our previous study on absolute quan-
tiﬁcation of liver phosphorus metabo-
lites (11). The study excluded patients
taking insulin or thiazolidinediones, or
presenting with islet cell antibodies and
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Pathophysiology/Complications
ORIGINAL ARTICLEdiabetes-related complications. Controls
had similar body mass and age, but normal
glucosetoleranceduringa75-goralglucose
tolerance test and had neither a family his-
tory of diabetes nor regular drug treatment.
None of the participants was physically
trained or performed regular intense exer-
cise.Theyhadnoevidenceforliverdiseases
and consumed ,20 g alcohol daily.
Of 24 individuals recruited, 3 did not
complete the experiment because they
refusedtocontinuetheMRSsession.Data
sets of three participants could not be
used due to low quality resulting from a
poor local homogeneity of the static
magnetic ﬁeld. Data from one individual
could not be used because of a technical
problem with the scanner. Thus, com-
plete MRS datasets for 17 individuals
were available for analyses (Table 1).
Type 2 diabetic patients showed
acceptable glycemic (A1C: 7.06 6
0.98% vs. 5.53 6 0.27% in controls;
P = 0.001) and lipid control on treat-
mentwith diet only (n =1 ),s ul f o n y l u r e a
only (n = 3), or combined with metfor-
min (n =5 )a n ds t a t i n s( n = 7). Medica-
tions were withdrawn at least 3 days
before the measurements. Measure-
ments of fATP and insulin sensitivity
were performed on different days under
identical conditions of overnight fasting
and withdrawal of medications.
Anthropometric measurements
Waist circumference was measured with
a cloth tape with participants upright.
Waist was deﬁned as the midpoint be-
tween the highest point of the iliac crest
andthelowestpartofthecostalmarginin
the midaxillary line (13).
Analytic procedures
Plasma glucose was measured by the
glucose oxidase method (Glucose Ana-
lyzer II, Beckman Instruments Inc., Ful-
lerton, CA) and plasma insulin by double
antibody radio immunoassay (11). All
other parameters were measured in the
clinical chemistry laboratory with stan-
dardized quality-controlled assays.
Peripheral and hepatic insulin
sensitivity
Whole-body glucose disposal (M, or M
related to plasma insulin [M/I]) and EGP
were measured in seven diabetic subjects
(three women/four men) and in six con-
trols (four women/two men) as described
previously (7), who exhibited identi-
cal demographics as the whole group.
Studies started at 6:30 A.M. with primed-
continuous infusion (5 min: 3.6 mg z kg
body wt
21 z fasting glucose [mg/dL]/90
[mg/dL]; 355 min: 0.036 mg z min
21 z kg
body wt
21)o fD-[6,6-
2H2]glucose (98%
enriched; CIL, Andover, MA). The eugly-
cemic (;5.5 mmol/L)-hyperinsulinemic
(;70 mU/L) clamp test was started at
10:00 A.M., with a primed continuous in-
fusionofhumanregularinsulin(Actrapid;
Novo Nordisk, Bagsvaerd, Denmark;
40 mU z [m body surface area]
22 z min
21)
for 240 min. A 20% dextrose infusion
labeled with D-[6,6-
2H2]glucose (2% en-
riched) according to the hot-glucose infu-
sion protocol was periodically adjusted to
maintain euglycemia (7).
MRS
After overnight fasting, volunteers
underwent a MRS protocol consisting of
two consecutive sessions with a break of
;30 min in a 3-T MR scanner (Bruker
Biospin, Ettlingen, Germany) using a
10-cm linear polarized surface coil tuned
to
1Ha n d
31P frequencies.
In session 1, subjects were supine in
the scanner with the coil positioned over
the lateral aspect of the liver. Axial and
oblique gradient echo images were ac-
quired during onebreath-holdeach.HCL
was measured using localized
1HM R S
(STEAM, 20 3 20 3 20 mm; 5 scans:
echo time, 15, 20, 30, 50, 70 ms; repeti-
tion time, 2.5 s) (Fig. 1A). Fat and water
peaks were integrated after phasing and
baseline adjustment using XWIN-NMR
software (Bruker Biospin, Ettlingen,
Germany). A 30-mm slab within the liver
was selected using 1D-ISIS encoding for
31P acquisitions (Fig. 1A). After a baseline
scan, alternated spectra with saturation of
the g-ATP resonance frequency and the
frequency mirrored relative to the PI reso-
nance were acquired (Fig. 1B). In
addition, a combined saturation transfer
inversion recovery experiment was per-
formed in each individual to determine
the effective longitudinal relaxation time
(T1*). Spectra were phased and baseline
corrected. The peak amplitude was used
forquantiﬁcationbecauseonlypeakratios
between consecutive scans were used as
described (12).
In session 2, lasting ;50 min, the
subjects were prone in the scanner on
top of the surface coil with the lateral as-
pect of the liver over the coil center. After
shimming, gradient echo-based images
were acquired during one breath-hold.
A 3-dimensional k-space weighted chem-
ical shift imaging sequence (ﬁeld of view:
20 3 20 3 20 cm, repetition time: 1 s,
bandwidth: 5 kHz, 2,048 acquisitions in
34 min) was applied, reconstructed, and
quantiﬁed ofﬂine using custom-made
software in combination with jMRUI/
AMARES, as described (12,14).
Calculations and analyses
Water and lipid signals were nonlinearly
ﬁtted as a single exponential for T2 cor-
rection. HCL were calculated as lipids/
(water + lipids) 3 100. The chemical ex-
change constant,k ofthesaturationtrans-
fer experiment is assessed from the PI
signal before (M0) and after saturation of
g-ATP (Ms). Then, k is calculated as k =
1/T1*3(12Ms/M0),andfATPasfATP=
k 3 PI.
Ratesofglucoseappearance(Ra)were
calculated by dividing the tracer (D-
[6,6-
2H2]glucose) infusion rate multiplied
by tracer enrichment by the percent of
Table 1—Anthropometric and laboratory parameters
Variable Type 2 diabetes Control
N (female) 9 (3) 8 (4)
Age (years) 57.7 6 6.1 60.1 6 4.4
Height (cm) 174 6 11 174 6 10
Body weight (kg) 82 6 14 78 6 17
BMI (kg/m
2) 26.9 6 3.4 25.1 6 3.9
A1C (%) 7.06 6 0.98* 5.57 6 0.27
Waist circumference (cm) 100 6 10 88 6 19
Fasting plasma glucose (mmol/L) 8.8 6 1.9* 5.3 6 0.6
Fasting plasma insulin (mU/L) 12.1 6 3.9 8.5 6 2.0
Serum LDL cholesterol (mg/dL) 119 6 22 146 6 33
Serum HDL cholesterol (mg/dL) 62 6 95 9 6 10
Plasma triglyceride (mg/dL) 163 6 80 128 6 79
GGT (units/L) 34 6 17 27 6 9
AST (units/L) 22 6 52 4 6 5
Data are expressed as mean 6 SD, unless indicated otherwise. *P , 0.001, signiﬁcant differences between
groups.
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ing the tracer infusion rate. During the
clamp, Ra was calculated using Steele’s
nonsteadystateequations.EGPwascalcu-
lated from the difference between Ra and
mean glucose infusion rates. Insulin-
mediated EGP represents EGP during the
last30minoftheclamp.EGPsuppression
wascalculatedas1003[(12EGPinsulin-
mediated)/(EGP baseline)].
Data are presented as means 6 SD
and compared between the groups using
the two-tailed Student t test. Relation-
ships between variables were analyzed
with Pearson correlations for normally
distributed data and with Spearman cor-
relations for the scattered HCL values.
Regression analyses for the dependent
variables fATP and PI were done using
the independent variables of age, BMI,
waist circumference, HCL, alanine ami-
notransferase, A1C, EGP, and FFA sup-
pression, M/I, serum triglycerides, and
low-density lipoprotein.
RESULTS—Diabetic participants had
67% higher fasting plasma glucose con-
centrations, 27% higher A1C, and similar
body weight, but tended to have greater
waist circumference (P = 0.167) than
controls (Table 1). Insulin sensitivity
was 29% (M) and 45% (M/I) lower in di-
abetic volunteers than in controls, con-
ﬁrming peripheral insulin resistance
(Table 2).
Mean HCL content was not different
betweengroups(Table2).Thedistribution
of the individual HCL values covered a
broad range from ,1 to 33% across the
groups, with values .5.5% in six diabetic
and ﬁve nondiabetic participants. Fasting
EGP was similar in both groups, whereas
EGP was completely suppressed during
insulin stimulation only in controls but
not in diabetic participants, indicating he-
patic insulin resistance. Fasting plasma
FFAs were comparable, but FFA suppres-
sion was lower in diabetic patients. Hepa-
tocellular fATP was 42% lower and k, the
chemical exchange rate constant, tended
to be lower in patients compared with
controls (Table 2). Previous medical treat-
ment with or without metformin did not
affect fATP (16.5 6 6.0 vs. 16.0 6 5.0
mmol/L/min).
fATP positively correlated with both
peripheral (M: r = 0.67, P = 0.01; M/I: r =
0.61, P = 0.03) and hepatic insulin resis-
tance (suppression of EGP: r =0 . 7 7 ,P =
0.002), even after adjustment for plasma
insulin during the clamp (r =0 . 8 4 ,P =
0.001) across all participants (Fig. 2A).
Also, k values related to M (r =0 . 6 7 ,P =
0.01) but not to M/I (r = 0.47, P = 0.11).
Furthermore, fATP correlated negatively
with waist circumference (r = 20.78 P =
0.001; Fig. 2B), fasting plasma glucose
(r = 20.58, P = 0.01), BMI (r = 20.55,
P = 0.02), HCL (r = 20.51, P = 0.04; Fig.
2C), and A1C (r = 20.50, P = 0.04). He-
patocellular PI (r = 0.77, P = 0.0003) re-
lated positively to fATP (Fig. 2D). After
adjusting for HCL, the relationships of
fATP with waist circumference (r = 20.81
P =0 . 0 0 1 ) ,M( r =0 . 6 6 ,P =0 . 0 2 ) ,M / I( r =
0.64,P=0.03),EGPsuppression(r=0. 72 ,
P = 0.009), BMI (20.54, P = 0.03), and
fasting plasma glucose (r = 20.52, P =
0.04) remained signiﬁcant. fATP did not
correlate signiﬁcantly with fasting FFA
(r =0 . 2 0 3 ,P = 0.507) or FFA suppression
(r =0 . 5 1 ,P =0 . 0 7 ) .
Multiple regression analysis for the
dependent variable fATP identiﬁed waist
circumference as the independent pre-
dictor of fATP (r
2 = 0.65, adjusted r
2 =
0.62, P = 0.001). Likewise, multiple re-
gression analysis for the dependent vari-
able PI identiﬁed waist circumference as
theindependentpredictorofPI(r
2=0.56,
adjusted r
2 =0 . 5 2 ,P = 0.003).
CONCLUSIONS—This study found
that patients with type 2 diabetes have
markedly lower hepatic ATP production
thannondiabeticindividualsofcomparable
age and body mass. Of note, this alteration
of fATP occurred without evidence for
clinical liver disease, as indicated by the
Figure 1—Liver MR data of one patient with type 2 diabetes. A: Axial slice through the liver
(gradient echo, prone position). The grid corresponds to the chemical shift imaging matrix. The
voxels surrounded by the bold white line were selected for quantiﬁcation. The MR spectrum
corresponding to the “3” in the image is shown on the right panel. B: MR spectra from the sat-
uration transfer experiment (solid line). The ATP resonance is completely suppressed, and the PI
signal is lower than in the baseline control experiment (dashed line).
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Hepatic ATP production in type 2 diabeteslack of a history of hepatitis, alcohol con-
sumption, or signiﬁcant elevation of liver
enzymes (11).
Across all subjects, hepatocellular
fATP correlated negatively with HCL, as
recently reported for the relationships
between hepatic absolute PI and ATP
concentrations and HCL (11). However,
we detected a clear difference in fATP
between diabetic and nondiabetic par-
ticipants, despite comparable HCL val-
ues and equal distribution of steatosis
(HCL .5.5%) in both groups (67% of
diabetic and 63% of nondiabetic partici-
pants). Thus, other factors than HCL more
likely explain the lower fATP in patients.
After adjustment for HCL, hepatic and
whole-body insulin sensitivity remained
tightly and negatively related to fATP.
Absolute hepatic concentrations of PI
and ATP are also associated with hepatic
but not with peripheral insulin sensitivity
(11). Under similar conditions of over-
night fasting, myocellular fATP correlates
negatively to peripheral insulin sensitiv-
ity,whichismostlyaccountedforbyskel-
etal muscle, but not to hepatic insulin
sensitivity (7). This suggests that hepato-
cellular fATP could serve as a better indi-
cator of overall insulin resistance than
myocellular fATP.
In type 2 diabetes, insulin resistance
develops as a result of inherited factors as
wellasfromacquired factors that resultin
glucolipotoxicityduetochronicelevation
of FFAs, triglycerides, or glucose (2,3). In
rats, a high-fat diet for 7 weeks induced
obesity, insulin resistance, and hepatic
steatosis and also reduced respiratory
capacity and increased oxidative stress
inlivermitochondria(15).Further, mito-
chondria from fatty rat liver have lower
amounts of ATP synthase protein (16).
A short-term high-fat diet also leads to
insulin resistance in liver, but not in skel-
etal muscle (17), whereas a hypocaloric
diet decreases both hepatic fat content
and insulin resistance within 48 h (18). In
conclusion,impairedenergymetabolismin
the liver could be an early defect in the
pathogenesis of type 2 diabetes.
The lack of a correlation of fATP with
circulating plasma triglycerides or FFAs
suggests that increased lipid availability
cannotexplain the abnormality of hepatic
fATP. However, hepatocellular fATP re-
lated negatively to BMI and even more
tightly to waist circumference, which
explained most of the variation of fATP.
Of note, waist circumference is the best
anthropometric marker of abdominal vis-
ceral fat (19), which suggests, but does
not prove, a role of visceral fat for hepatic
energy metabolism.
HepatocellularfATPfurtherrelatedto
short- and long-term glycemia, as mea-
sured by fasting plasma glucose and A1C,
so that defective hepatic energy metabo-
lism could also reﬂect deterioration of
glucose metabolism in the progression of
type 2 diabetes. Abnormalities in fATP
have been found in skeletal muscle not
only of patientswith overttype 2 diabetes
(7,20) but also of their nondiabetic ﬁrst-
degree relatives, who are at increased risk
for type 2 diabetes (8). Impairment of
ATP synthesis in skeletal muscle has
been further related to insulin resistance,
myocellular lipid deposition, and genetic
susceptibility to the onset of type 2diabe-
tes (21). To our knowledge, however,
no data on a similar association between
lipid contents, insulin sensitivity, and
ATP production, which also includes
ATP generation from glycolytic ﬂux,
have been reported in the livers of patients
with type 2 diabetes. Although our re-
sults suggest that abnormal phosphorus
metabolismrelatestohepaticinsulinresis-
tance and HCL, we cannot rule out that
reduced ATP turnover is rather a conse-
quence of reduced energy demand or al-
tered energy homeostasis that may relate
to increased lipid availability and hyper-
glycemia. In this case, impaired fATP
would result from chronic hyperglycemia
and/or insulin resistance due to glucose
toxicity. Of note, there is evidence that
insulin stimulates uptake of PI by way
of a sodium-dependent transporter, at
least in cultured rat hepatocytes, so that
desensitization of this system could lead
to lower hepatocellular PI levels (22).
Our MRS protocol is time-consuming,
which also explains the dropout rate in
this study. Alternatively, the tight rela-
tionship between hepatocellular fATP and
PI, which is a direct consequence of a
comparable rate constant, k, suggests that
quantiﬁcation of the absolute PI concen-
tration could be sufﬁcient for assessing
hepatic energy metabolism. Altered tissue
morphology could affect the MR relaxa-
tion rates, which in turn could affect the
absolute quantiﬁcation of metabolites and
fATP. This simpliﬁcation should, there-
fore, only be considered when there is
strong evidence against alterations in
MR relaxation times. The tight correlation
between ATP and PI (11) renders errors
due to altered MR relaxation times highly
unlikely. Participants in the current study
did not show clinical signs of cholestasis
or impaired liver function, as expressed
by normal results on liver enzyme tests
and function parameters, although we
cannot be completely certain because
we had no histologic conﬁrmation. Thus,
absolute quantiﬁcation of hepatic
31P
metabolites (11,12), together with k
fromthisstudy,appearstobeaclinically
applicable measure of hepatic energy
metabolism. Even more, it appears that
waist circumference could also serve as
a viable predictor of hepatic ATP pro-
duction.
Nevertheless, some limitations of the
current study need to be considered. We
studied elderly volunteers who had a
meanageof~60years,whichmightresult
in lower fATP analogous to data on
myocellular fATP(8).Theages ofdiabetic
and nondiabetic participants in this study
were similar, however, and fATP in these
elderly controls was almost identical to
that previously reported for young, lean,
healthy volunteers (12).
Finally, the saturation transfer exper-
iment provides a measure of total ATP
turnover, which includes cycling at the
Table 2—Liver fat, energy metabolism, and hepatic and peripheral insulin sensitivity
Variable Type 2 diabetes Control
HCL (% signal) 10.6 6 9.3 8.2 6 10.9
Absolute PI (mmol/L) 0.96 6 0.19* 1.38 6 0.38
k (s
21) 0.28 6 0.07 0.33 6 0.12
fATP (mmol z L
21 z min
21) 16.2 6 5.2† 28.0 6 13.0
EGP baseline (mg z kg
21 z min
21)1 . 6 6 0.3 1.8 6 0.4
EGP suppression (%) 72 6 15‡ 100 6 17
FFA baseline (mmol/L) 569 6 122 430 6 260
FFA suppression (%) 95 6 2* 97 6 2
M( m gz kg
21 z min
21)5 . 3 6 1.3§ 7.5 6 1.9
M/I (mg z kg
21 z min
21 z mU
21 z L) 0.06 6 0.03|| 0.11 6 0.02
Data are shown as mean 6 SD. Signiﬁcant differences between groups: *P = 0.011; †P = 0.025; ‡P = 0.009;
§P =0 . 0 0 3 ;| | P =0 . 0 0 5 .
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hydrogenase and 3-phosphoglycerate ki-
nase of the glycolytic and gluconeogenic
pathways (23). Because fasting EGP was
comparablebetweenbothgroups,despite
different degrees of glycemia, a variable
contribution of cycling is rather unlikely.
Finally, some spectra of the saturation
transfer experiment contained residual
phosphocreatine resulting from a minor
compromise between optimizing locali-
zation and signal-to-noise ratio. Of note,
the phosphocreatine is dominating skele-
tal muscle spectra, implying the contam-
ination in PI, which determines fATP, is
lower by an order of magnitude. More-
over, chemical shift displacement shifts
the PI signal further inward into the liver.
The phosphodiester signals appear af-
fected by the saturation pulse (Fig. 1A);
thiscould,besidesoff-resonanceeffects,in-
dicatechemicalexchangesuchasATPused
in phosphodiesterase formation (24).
In conclusion, patients with type 2
diabetes without clinical liver disease
exhibit lower ATP production than non-
diabetic otherwise comparable individu-
als. The reduction in ﬂux through ATP
synthesis depends primarily on the lower
hepatic PI and ATP concentrations. Insu-
lin resistance relates to the perturbed he-
patic energy metabolism, which can be at
least be partly explained by fat mass as
assessed from waist circumference.
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